Dashboard
1
The company has declared Positive results for the last 10 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CNY 2,163.79 MM
- NET PROFIT(HY) At CNY 1,187.76 MM has Grown at 59.72%
- ROCE(HY) Highest at 34.9%
2
With ROE of 29.16%, it has a attractive valuation with a 7.88 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 43,056 Million (Large Cap)
27.00
NA
0.00%
-0.50
29.94%
6.63
Revenue and Profits:
Net Sales:
1,359 Million
(Quarterly Results - Sep 2025)
Net Profit:
565 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.33%
0%
4.33%
6 Months
-10.58%
0%
-10.58%
1 Year
28.27%
0%
28.27%
2 Years
125.74%
0%
125.74%
3 Years
309.87%
0%
309.87%
4 Years
306.71%
0%
306.71%
5 Years
213.73%
0%
213.73%
Shanghai Allist Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
443.87%
EBIT Growth (5y)
50.71%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
0.60
Tax Ratio
13.82%
Dividend Payout Ratio
20.46%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
27.87%
ROE (avg)
10.46%
Valuation key factors
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
7.88
EV to EBIT
23.97
EV to EBITDA
23.45
EV to Capital Employed
20.71
EV to Sales
10.31
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
86.39%
ROE (Latest)
29.16%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
1,359.30
1,275.40
6.58%
Operating Profit (PBDIT) excl Other Income
618.60
603.10
2.57%
Interest
0.00
0.00
Exceptional Items
9.00
11.60
-22.41%
Consolidate Net Profit
564.50
640.70
-11.89%
Operating Profit Margin (Excl OI)
455.10%
464.60%
-0.95%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 6.58% vs 16.11% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -11.89% vs 56.08% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,516.00
1,991.60
76.54%
Operating Profit (PBDIT) excl Other Income
1,515.00
589.90
156.82%
Interest
0.10
0.20
-50.00%
Exceptional Items
28.90
22.70
27.31%
Consolidate Net Profit
1,429.80
644.20
121.95%
Operating Profit Margin (Excl OI)
419.60%
276.00%
14.36%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 76.54% vs 152.48% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 121.95% vs 393.64% in Dec 2023
About Shanghai Allist Pharmaceuticals Co., Ltd. 
Shanghai Allist Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






